Learn About Dr. Yaqubi

I am board-certified in both psychiatry and psychosomatic medicine, with a specialized focus on Mood and Anxiety disorders. I employ a collaborative and holistic approach to develop personalized treatment plan for each patient. I value my patients’ questions as they open the door to dialogue and a deeper understanding, allowing us to determine the best treatment for each individual. I have found that understanding and empathizing with my patients' emotional pain is crucial for developing a strong therapeutic rapport.

Depression and Anxiety can severely impact our ability to connect with others, often leaving us feeling isolated. At our practice, we work closely with patients, finding a right path to help them reconnect with themselves and their loved ones.

Psychotherapy and Medication Management are the first lines of treatment for depression and anxiety. I also work with patients with treatment resistant depression and anxiety. I find Ketamine and Transcranial Magnetic Stimulation (TMS) a non-invasive therapeutic tool that can play a crucial role for those with treatment-resistant mood and anxiety.

  • Dr. Yaqubi completed his Psychiatry Residency, followed by a Fellowship in Psychosomatic Medicine / Consultation-Liaison Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City.

    Following his fellowship, Dr. Yaqubi served at the Recanati/Miller Transplant Institute at Mount Sinai Hospital as an Assistant Professor of Psychiatry, where he taught and supervised medical students, psychiatry residents, and fellows. He later continued as an Assistant Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai / Beth Israel Hospital, leading a multidisciplinary psychiatric emergency team that included physicians, nurses, and social workers.

    After relocating to California, Dr. Yaqubi founded PathWave Psychiatry, a mental health clinic in Berkeley, California, dedicated to providing innovative, evidence-based psychiatric care. His practice specializes in interventional psychiatry, offering advanced treatments such as Transcranial Magnetic Stimulation (TMS), esketamine (Spravato) therapy, and comprehensive medication management for patients with treatment-resistant depression and anxiety.

    • Board certified, American Board of Psychiatry and Neurology

    • Board Certified, American Board of Psychosomatic Medicine/ Consultation-Liaison Psychiatry

    • Member, American Psychiatric Association

    • Member, Clinical TMS Society

  • James W. Murrough, Sahab Yaqubi, Sehrish Sayed and Dennis S. Charney. “Emerging Drugs for the Treatment of Anxiety”. Expert Opin Emerg Drugs 2015 May 26:1-14. Cited in PubMed; PMID: 26012843

    Hamid M Abdolmaleky, Sahab Yaqubi, Panos Papageorgis, Arthur W. Lambert, Sait Ozturk, Vadivelu Sivaraman and Sam Thiagalingam. “Epigenetic dysregulation of HTR2A in the Brain of patients with schizophrenia and bipolar disorder”. Schizophrenia Research 129 (2011) pp. 183-190. Cited in PubMed; PMID: 21550210

    Rahim Shafa, Hamid Abdolmaleky, Sahab Yaqubi, Casandra L Smith, Nassir Ghaemi. Entacapone as an Anti-Craving Treatment in Substance Abuse and Dependence. The American Journal on Addictions 17(4), pp. 331-332, 2008